Form 4: Adaptive Biotechnologies Corp: Chief Scientific Officer Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Harlan S Robins, Chief Scientific Officer of Adaptive Biotechnologies Corp, reports changes in beneficial ownership of common stock on March 4, 2024.
Summary
- On March 4, 2024, Harlan S Robins, the Chief Scientific Officer of Adaptive Biotechnologies Corp, reported changes in their beneficial ownership of the company's common stock.
- The transaction involved the acquisition of 354,610 shares of common stock at $0 and the disposal of 1,021,180 shares.
- Following the reported transaction, the total amount of common stock beneficially owned by Robins is not specified.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting changes in beneficial ownership, which doesn't inherently convey positive or negative sentiment. It's a neutral disclosure.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It allows investors to monitor the actions of key personnel and their potential impact on the company's stock.
Stakeholder Impact
- Shareholders may be interested in the trading activity of company insiders as it can provide insights into management's perspective on the company's value and prospects.
Key Dates
| Date | Description |
|---|---|
| 03/04/2024 | Date of transaction involving common stock. |
| 03/06/2024 | Date of signature by Attorney-in-Fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.